Radiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France.
INSERM, U1030, F-94805, Villejuif, France.
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):187-195. doi: 10.1007/s00259-017-3824-z. Epub 2017 Sep 15.
We investigated whether a score combining baseline neutrophilia and a PET biomarker could predict outcome in patients with locally advanced cervical cancer (LACC).
Patients homogeneously treated with definitive chemoradiation plus image-guided adaptive brachytherapy (IGABT) between 2006 and 2013 were analyzed retrospectively. We divided patients into two groups depending on the PET device used: a training set (TS) and a validation set (VS). Primary tumors were semi-automatically delineated on PET images, and 11 radiomics features were calculated (LIFEx software). A PET radiomic index was selected using the time-dependent area under the curve (td-AUC) for 3-year local control (LC). We defined the neutrophil SUV grade (NSG = 0, 1 or 2) score as the number of risk factors among (i) neutrophilia (neutrophil count >7 G/L) and (ii) high risk defined from the PET radiomic index. The NSG prognostic value was evaluated for LC and overall survival (OS).
Data from 108 patients were analyzed. Estimated 3-year LC was 72% in the TS (n = 69) and 65% in the VS (n = 39). In the TS, SUV was selected as the most LC-predictive biomarker (td-AUC = 0.75), and was independent from neutrophilia (p = 0.119). Neutrophilia (HR = 2.6), high-risk SUV (SUV > 10, HR = 4.4) and NSG = 2 (HR = 9.2) were associated with low probability of LC in TS. In multivariate analysis, NSG = 2 was independently associated with low probability of LC (HR = 7.5, p < 0.001) and OS (HR = 5.8, p = 0.001) in the TS. Results obtained in the VS (HR = 5.2 for OS and 3.5 for LC, p < 0.02) were promising.
This innovative scoring approach combining baseline neutrophilia and a PET biomarker provides an independent prognostic factor to consider for further clinical investigations.
我们研究了基线嗜中性粒细胞与 PET 生物标志物联合评分是否可预测局部晚期宫颈癌(LACC)患者的结局。
回顾性分析了 2006 年至 2013 年间接受根治性放化疗联合图像引导自适应近距离治疗(IGABT)的同质治疗患者。根据使用的 PET 设备将患者分为两组:训练集(TS)和验证集(VS)。在 PET 图像上半自动勾画原发肿瘤,并计算 11 个放射组学特征(LIFEx 软件)。使用 3 年局部控制(LC)的时间依赖性曲线下面积(td-AUC)选择 PET 放射组学指数。我们将中性粒细胞 SUV 分级(NSG=0、1 或 2)定义为风险因素(i)中性粒细胞增多(中性粒细胞计数>7 G/L)和(ii)从 PET 放射组学指数定义的高危因素的数量。评估 NSG 对 LC 和总生存(OS)的预后价值。
对 108 例患者的数据进行了分析。在 TS(n=69)和 VS(n=39)中,估计 3 年 LC 分别为 72%和 65%。在 TS 中,SUV 是最能预测 LC 的生物标志物(td-AUC=0.75),与中性粒细胞增多无关(p=0.119)。中性粒细胞增多(HR=2.6)、高风险 SUV(SUV>10,HR=4.4)和 NSG=2(HR=9.2)与 TS 中 LC 低概率相关。多变量分析显示,NSG=2 与 LC(HR=7.5,p<0.001)和 OS(HR=5.8,p=0.001)的低概率独立相关。在 VS 中(OS 和 LC 的 HR 分别为 5.2 和 3.5,p<0.02)得到了有希望的结果。
这种将基线嗜中性粒细胞与 PET 生物标志物相结合的创新评分方法为进一步的临床研究提供了一个独立的预后因素。